dentalcorp Holdings Valuation
Is 6A7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6A7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6A7 (€5.9) is trading below our estimate of fair value (€19.39)
Significantly Below Fair Value: 6A7 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6A7?
Key metric: As 6A7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 6A7's PS Ratio? | |
|---|---|
| PS Ratio | 1.2x |
| Sales | CA$1.51b |
| Market Cap | CA$1.77b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 15.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6A7's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.8x | ||
SYAB SYNLAB | 1x | 4.4% | €2.5b |
FME Fresenius Medical Care | 0.6x | 3.8% | €12.4b |
V3V VITA 34 | 0.9x | 3.1% | €72.5m |
FRE Fresenius SE KGaA | 0.8x | 3.6% | €18.8b |
6A7 dentalcorp Holdings | 1.2x | 9.8% | €1.8b |
Price-To-Sales vs Peers: 6A7 is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.8x).
Price to Sales Ratio vs Industry
How does 6A7's PS Ratio compare vs other companies in the DE Healthcare Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
TLIK Arzneiwerk VIDA | 0.08x | n/a | US$4.67m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 6A7 is expensive based on its Price-To-Sales Ratio (1.2x) compared to the European Healthcare industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is 6A7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | 1.7x |
Price-To-Sales vs Fair Ratio: 6A7 is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €5.90 | €8.28 +40.4% | 4.4% | €8.88 | €7.85 | n/a | 6 |
| Nov ’25 | €6.15 | €7.33 +19.2% | 4.9% | €7.83 | €6.67 | n/a | 9 |
| Oct ’25 | €5.30 | €6.86 +29.4% | 14.6% | €7.63 | €4.05 | n/a | 10 |
| Sep ’25 | €4.88 | €6.86 +40.5% | 14.6% | €7.63 | €4.05 | n/a | 10 |
| Aug ’25 | €4.96 | €6.72 +35.4% | 14.2% | €7.66 | €4.06 | n/a | 10 |
| Jul ’25 | €5.45 | €6.78 +24.3% | 14.0% | €7.76 | €4.12 | n/a | 10 |
| Jun ’25 | €4.50 | €6.77 +50.5% | 14.0% | €7.76 | €4.12 | n/a | 10 |
| May ’25 | €4.28 | €6.84 +59.8% | 15.6% | €7.83 | €4.15 | n/a | 11 |
| Apr ’25 | €4.54 | €6.80 +49.7% | 16.3% | €7.81 | €4.14 | n/a | 10 |
| Mar ’25 | €4.40 | €6.85 +55.7% | 16.5% | €7.82 | €3.94 | n/a | 10 |
| Feb ’25 | €4.40 | €6.77 +53.8% | 16.6% | €7.88 | €3.97 | n/a | 10 |
| Jan ’25 | €4.66 | €6.84 +46.9% | 16.1% | €7.66 | €3.86 | n/a | 10 |
| Dec ’24 | €3.60 | €6.84 +90.1% | 16.1% | €7.66 | €3.86 | n/a | 10 |
| Nov ’24 | €3.66 | €8.25 +125.5% | 18.4% | €10.27 | €4.11 | €6.15 | 10 |
| Oct ’24 | €4.06 | €8.69 +114.2% | 19.0% | €10.88 | €4.08 | €5.30 | 11 |
| Sep ’24 | €4.42 | €8.69 +96.5% | 19.0% | €10.88 | €4.08 | €4.88 | 11 |
| Aug ’24 | n/a | €9.48 0% | 8.5% | €11.16 | €8.72 | €4.96 | 10 |
| Jul ’24 | n/a | €9.48 0% | 8.5% | €11.16 | €8.72 | €5.45 | 10 |
| Jun ’24 | n/a | €9.22 0% | 8.0% | €10.92 | €8.53 | €4.50 | 9 |
| May ’24 | n/a | €9.60 0% | 6.6% | €10.76 | €8.74 | €4.28 | 9 |
| Apr ’24 | n/a | €9.60 0% | 6.6% | €10.76 | €8.74 | €4.54 | 9 |
| Mar ’24 | n/a | €10.17 0% | 5.1% | €11.10 | €9.37 | €4.40 | 9 |
| Feb ’24 | n/a | €10.67 0% | 4.9% | €11.61 | €9.80 | €4.40 | 10 |
| Jan ’24 | n/a | €10.67 0% | 4.9% | €11.61 | €9.80 | €4.66 | 10 |
| Dec ’23 | n/a | €10.67 0% | 4.9% | €11.61 | €9.80 | €3.60 | 10 |
| Nov ’23 | n/a | €12.24 0% | 5.4% | €13.32 | €11.47 | €3.66 | 11 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.1%
1Y
16.0%
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.0%
1Y
-38.8%
OrbusNeich Medical Group Holdings
HK$3.4b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
Q8T
HK$0.51
7D
12.2%
1Y
-43.3%